Key result
Small-molecule myosin inhibitors function primarily as noncompetitive inhibitors of myosin ATPase activity, providing valuable tools for biological research and potential leads for targeted therapeutics.
Small-molecule myosin inhibitors provide valuable scientific tools for characterizing intracellular processes and offer potential therapeutic avenues for diseases involving myosin dysfunction, such as hypertrophic cardiomyopathy.
Advances in screening and computational methods have enhanced recent efforts to discover/design small-molecule protein inhibitors. One attractive target for inhibition is the myosin family of motor proteins. Myosins function in a wide variety of cellular processes, from intracellular trafficking to cell motility, and are implicated in several human diseases (e.g., cancer, hypertrophic cardiomyopathy, deafness and many neurological disorders). Potent and selective myosin inhibitors are, therefore, not only a tool for understanding myosin function, but are also a resource for developing treatments for diseases involving myosin dysfunction or overactivity. This review will provide a brief overview of the characteristics and scientific/therapeutic applications of the presently identified small-molecule myosin inhibitors before discussing the future of myosin inhibitor and activator design.
No takes yet. Share an insight, caveat, or question.
Bond et al. (2012) conducted a review in Myosin dysfunction or overactivity. Small-molecule myosin inhibitors was evaluated. Small-molecule myosin inhibitors function primarily as noncompetitive inhibitors of myosin ATPase activity, providing valuable tools for biological research and potential leads for targeted therapeutics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: